Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ISONASDAQ:NAUTNASDAQ:OMICNASDAQ:PRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeISOIsoPlexis$0.76$0.86$0.60▼$5.10$30.28M1.3268,375 shsN/ANAUTNautilus Biotechnology$0.87-1.8%$0.83$0.66▼$3.09$111.21M1.41115,815 shs95,494 shsOMICSingular Genomics Systems$20.01$20.01$5.34▼$23.41$50.83M1.8343,037 shsN/APREPrenetics Global$5.79-0.2%$4.42$3.09▼$6.99$70.74M-0.2617,137 shs4,854 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceISOIsoPlexis0.00%0.00%0.00%0.00%0.00%NAUTNautilus Biotechnology-4.90%+25.96%+12.72%-48.74%-69.17%OMICSingular Genomics Systems0.00%0.00%0.00%+0.35%+55.26%PREPrenetics Global+8.41%+11.56%+56.33%+6.52%-3.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationISOIsoPlexisN/AN/AN/AN/AN/AN/AN/AN/ANAUTNautilus Biotechnology2.676 of 5 stars3.02.00.00.02.94.20.6OMICSingular Genomics SystemsN/AN/AN/AN/AN/AN/AN/AN/APREPrenetics Global3.1365 of 5 stars3.55.00.00.03.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceISOIsoPlexis 0.00N/AN/AN/ANAUTNautilus Biotechnology 2.00Hold$2.42179.09% UpsideOMICSingular Genomics Systems 2.00Hold$6.50-67.52% DownsidePREPrenetics Global 3.00Buy$9.0055.44% UpsideCurrent Analyst Ratings BreakdownLatest ISO, NAUT, PRE, and OMIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/28/2025NAUTNautilus BiotechnologyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.50(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookISOIsoPlexis$16.76M1.81N/AN/A$1.04 per share0.73NAUTNautilus BiotechnologyN/AN/AN/AN/A$2.12 per shareN/AOMICSingular Genomics Systems$2.91M17.47N/AN/A$73.25 per share0.27PREPrenetics Global$30.62M2.31N/AN/A$17.22 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateISOIsoPlexis-$106M-$2.70N/AN/AN/A-632.41%-127.86%-71.41%N/ANAUTNautilus Biotechnology-$63.67M-$0.54N/AN/AN/AN/A-28.85%-24.93%7/29/2025 (Estimated)OMICSingular Genomics Systems-$94.82M-$35.11N/A∞N/A-3,237.89%-57.87%-37.90%N/APREPrenetics Global-$62.72M-$3.99N/AN/AN/A-191.73%-16.45%-13.34%6/17/2025 (Estimated)Latest ISO, NAUT, PRE, and OMIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2025Q1 2025NAUTNautilus Biotechnology-$0.14-$0.13+$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthISOIsoPlexisN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/AOMICSingular Genomics SystemsN/AN/AN/AN/AN/APREPrenetics Global$2.8048.36%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioISOIsoPlexis1.124.062.50NAUTNautilus BiotechnologyN/A16.6516.65OMICSingular Genomics Systems0.047.376.67PREPrenetics GlobalN/A1.401.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipISOIsoPlexis44.91%NAUTNautilus Biotechnology50.71%OMICSingular Genomics Systems65.80%PREPrenetics Global25.01%Insider OwnershipCompanyInsider OwnershipISOIsoPlexis6.40%NAUTNautilus Biotechnology41.10%OMICSingular Genomics Systems22.20%PREPrenetics Global7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableISOIsoPlexis45939.76 million37.22 millionNot OptionableNAUTNautilus Biotechnology130126.15 million74.71 millionOptionableOMICSingular Genomics Systems2202.54 million1.97 millionNo DataPREPrenetics Global112.21 million11.25 millionNot OptionableISO, NAUT, PRE, and OMIC HeadlinesRecent News About These CompaniesPrenetics Global (NASDAQ:PRE) Shares Down 2.6% - Should You Sell?May 15 at 2:47 AM | marketbeat.comPrenetics Global Full Year 2024 Earnings: Misses ExpectationsMay 3, 2025 | finance.yahoo.comPrenetics Global Limited (PRENW)March 19, 2025 | ca.finance.yahoo.comPrenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements MarketMarch 18, 2025 | markets.businessinsider.comPrenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements MarketMarch 18, 2025 | globenewswire.comPrenetics to Participate in the 37th Annual ROTH ConferenceMarch 11, 2025 | finance.yahoo.comPrenetics Reports Strong 2024 Results and Optimistic 2025 OutlookMarch 5, 2025 | tipranks.comPrenetics Global Limited Reports 93.5% Revenue Growth in Q4 2024 and Provides 2025 Financial GuidanceMarch 5, 2025 | quiverquant.comPrenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 GuidanceMarch 5, 2025 | globenewswire.comNYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 14th + KARMAN POPS DOUBLE DIGIT IPOFebruary 14, 2025 | prnewswire.comPrenetics Global Ltd trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPrenetics Global Ltd trading resumesFebruary 12, 2025 | markets.businessinsider.comPrenetics partners with Humanity Protocol, launches crypto strategic reserveFebruary 11, 2025 | markets.businessinsider.comPrenetics Partners with Humanity Protocol to Enhance Blockchain-Based Identity Verification and Invests in Digital AssetsFebruary 11, 2025 | quiverquant.comNasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic ReserveFebruary 11, 2025 | globenewswire.comPrenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David BeckhamJanuary 22, 2025 | markets.businessinsider.comCantor Fitzgerald Sticks to Their Buy Rating for Prenetics Group (PRE)January 16, 2025 | markets.businessinsider.comIM8, Co-Founded by David Beckham, Achieves NSF Certified for Sport® Certification for Daily Ultimate Essentials SupplementJanuary 15, 2025 | quiverquant.comPrenetics' IM8 Achieves Prestigious NSF Certified for Sport® for Daily Ultimate EssentialsJanuary 15, 2025 | globenewswire.comDavid Beckham Joins Prenetics as Strategic Investor for IM8 Health BrandJanuary 14, 2025 | lawyer-monthly.comHow David Beckham plans to win the $152 billion supplements businessJanuary 14, 2025 | fastcompany.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBroadcom's VMware Deal Lifts AVGO Despite Complaints By Leo Miller | April 28, 2025View Broadcom's VMware Deal Lifts AVGO Despite Complaints UPS Stock Forecast: Rebound Underway for United Parcel Service?By Thomas Hughes | May 4, 2025View UPS Stock Forecast: Rebound Underway for United Parcel Service?Time to Buy Alibaba and PDD After Tariff Exemptions?By Gabriel Osorio-Mazilli | April 17, 2025View Time to Buy Alibaba and PDD After Tariff Exemptions?Warning or Opportunity After Super Micro Computer's EarningsBy Gabriel Osorio-Mazilli | May 5, 2025View Warning or Opportunity After Super Micro Computer's EarningsISO, NAUT, PRE, and OMIC Company DescriptionsIsoPlexis NASDAQ:ISOIsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Nautilus Biotechnology NASDAQ:NAUT$0.87 -0.02 (-1.78%) As of 04:00 PM EasternNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Singular Genomics Systems NASDAQ:OMIC$20.01 0.00 (0.00%) As of 02/21/2025Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.Prenetics Global NASDAQ:PRE$5.79 -0.01 (-0.17%) As of 03:44 PM EasternPrenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
